BioCardia

Autologous cell therapy for cardiovascular disease

BCDA · Nasdaq · United States

Share price · BCDA

$0.77-0.20 (-20.85%) 3M

close as of 2026-11-18 · 24h delayed · vol 23K (0.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BCDA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 20 Oct 2026+15.9%
  2. 17 Sep 2026-11.2%
  3. 14 Jul 2026-12.1%

    Nothing announced by BCDA that day or the session before.

  4. 7 Jul 2026-12.8%

    Nothing announced by BCDA that day or the session before.

  5. 12 Jun 2026+10.0%
  6. 9 Jun 2026-6.5%
  7. 8 Jun 2026-10.7%
  8. 5 Jun 2026+12.0%
  9. 18 May 2026-10.9%
  10. 4 Mar 2026-6.3%

Share of unusual movement by asset

For each asset, the share of BCDA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Cardiac cell therapyCell therapy
Heart Failure
Ischemic Heart Failure

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$1.2M$2.2M$1.8M-$1.7M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$0.9M$4.1M$1.6M-$1.7M operating cash flowreport ↗
2026-Q1—$1.2M$0.9M$2.3M-$1.7M operating cash flowreport ↗
2025-Q3$0$0.9M$5.3M$1.5M-$1.7M operating cash flowreport ↗
2025-Q2$0$1.4M$1.0M$2.0M-$1.6M operating cash flowreport ↗
2025-Q1$0$1.5M$0.9M$2.7M-$1.6M operating cash flowreport ↗
2024-Q3$0$0.9M$4.9M$1.7M-$2.6M operating cash flowreport ↗
2024-Q2$0$0.8M$1.4M$1.6M-$1.3M operating cash flowreport ↗
2024-Q1$0.1M$1.2M$0.9M$2.3M-$1.5M operating cash flowreport ↗
2023-Q3$0.4M$1.9M$1.8M$2.6M-$2.4M operating cash flowreport ↗
2023-Q2<$0.1M$2.3M$4.3M$3.4M-$3.1M operating cash flowreport ↗
2023-Q1$0.1M$2.4M$4.9M$3.5M-$2.6M operating cash flowreport ↗
2022-Q3$0.2M$2.1M$6.7M$3.1M-$2.0M operating cash flowreport ↗
2022-Q2$1.0M$2.3M$8.6M$2.5M-$2.6M operating cash flowreport ↗
2022-Q1$0.1M$2.2M$9.9M$3.3M-$2.9M operating cash flowreport ↗
2021-Q3$0.8M$2.2M$16M$2.7M-$2.6M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$5.0M$2.5M$2.1M-$7.4M operating cash flowreport ↗

For FY2025, BioCardia reported revenue of $0M, down 100.0% YoY from $0.06M, and R&D spend of $4.96M, up 13.0% YoY. Cash and equivalents were $2.5M, with a net loss of $8.23M and quarterly net burn of $8.23M.

Clinically, the company presented two-year CardiAMP HF results at ACC 2025 and echocardiography outcomes at THFT in March 2026, while its Helix Pre-Submission was accepted by FDA with a meeting expected in Q2 2026. CardiAMP HF II enrollment is ongoing with four activated sites, CardiAMP CMI roll-in results were submitted for Euro PCR, and the CardiALLO low-dose cohort completed without treatment-emergent adverse events. CMS has designated the CardiAMP trials for Medicare coverage.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.1M$4.4M$2.4M$2.0M-$8.0M operating cash flowreport ↗
2023-FY$0.5M$7.7M$4.9M$2.9M-$10.0M operating cash flowreport ↗
2022-FY$1.4M$8.8M$7.4M$3.0M-$11M operating cash flowreport ↗
2021-FY$1.0M$8.6M$13M$3.2M-$10M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 34 purchases ($170K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-16Altman Peter · director, President and CEOOpen-market purchase300$0.95$285Form 4
2026-10-15Altman Peter · director, President and CEOOpen-market purchase200$0.95$190Form 4
2026-09-29Altman Peter · director, President and CEOOpen-market purchase1,000$1.03$1KForm 4
2026-09-23Altman Peter · director, President and CEOOpen-market purchase1,900$1.05$2KForm 4
2026-09-03Altman Peter · director, President and CEOOpen-market purchase800$1.09$872Form 4
2026-08-17Altman Peter · director, President and CEOOpen-market purchase5,400$0.93$5KForm 4
2026-08-13Altman Peter · director, President and CEOOpen-market purchase1,900$0.92$2KForm 4
2026-07-29Altman Peter · director, President and CEOOpen-market purchase5,000$0.78$4KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 18 reporting institutions held 0.7M shares ($806K, 4.5% of shares outstanding).

#InstitutionSharesValue
1CM Management, LLC130,000$157K
2VANGUARD CAPITAL MANAGEMENT LLC124,591$151K
3GEODE CAPITAL MANAGEMENT, LLC94,287$114K
4VANGUARD FIDUCIARY TRUST CO66,270$80K
5CITADEL ADVISORS LLC63,384$77K
6SUSQUEHANNA INTERNATIONAL GROUP, LLP38,827$47K
7Pingora Partners LLC35,739$43K
8BROWN ADVISORY INC35,538$43K
9XTX Topco Ltd24,270$29K
10COMMONWEALTH EQUITY SERVICES, LLC18,283$22K
11TWO SIGMA SECURITIES, LLC14,780$18K
12RENAISSANCE TECHNOLOGIES LLC13,900$17K
13MORGAN STANLEY3,105$4K
14Tower Research Capital LLC (TRC)2,978$4K
15Vanguard Global Advisers, LLC268$324